The neuropathological hallmark of Parkinson disease (PD) is abnormal accumulation of a-synuclein (a-syn). Demonstrating pathological a-syn in live patients would be useful for identifying and monitoring PD patients. To date, however, imaging and biofluid approaches have not permitted premortem assessment of pathological a-syn. a-syn pathology in the peripheral nervous system of patients with PD has been demonstrated in studies dating back more than 40 years. More recent work suggests that colon, submandibular gland and skin biopsies could be useful as expedient biomarkers but histological differentiation of pathological and normal peripheral a-syn has been challenging and multiple research groups have reported variable results. A variety of immunohistochemical methods have been employed but almost all studies to date originated at single centers with no independent, blinded replication. To address these issues, the Michael J. Fox Foundation for Parkinson's Research sponsored a series of meetings and investigations by several research groups with relevant experience. The major finding reported herein was that biopsies can be used to distinguish PD patients from normal subjects. However, full assessment of the clinical potential of biopsy will only be achieved through large, multicenter trials in which both the initial detection methodology and histology have been assessed by blinded panels of pathologists.
INTRODUCTION Peripheral Tissue Synucleinopathy as a Biomarker
The cardinal neuropathological hallmark of Parkinson disease (PD) is a-synuclein (a-syn) aggregation and accumulation in the brain. Not only are a-syn aggregates the major component of Lewy bodies and neurites but substantial clinical and preclinical evidence have established the involvement of a-syn in the pathogenesis of PD. For these reasons, a-syn is an extremely attractive biomarker of PD diagnosis, progression, and ultimately drug efficacy. In the absence of an imaging tracer to measure a-syn aggregates in living patients directly, researchers and clinicians have investigated a-syn in the extracellular fluid compartment closest to the brain, the CSF. Although many studies have demonstrated a significant reduction in CSF a-syn in PD patients compared with healthy controls, inter-and intrasubject variability, and interlaboratory variability are high; moreover, the effects of preanalytical factors such as storage and handling of fluid samples have proven problematic.
The Braak hypothesis, which is built in part on earlier work by Wakabayashi et al (1) (2) (3) (4) (5) (6) , posits that a-syn pathology may begin in the peripheral nervous system well before a-syn accumulation in the brain or alterations in CSF are evident (7) (8) (9) . Although at present there is no conclusive evidence supporting this "body-first" hypothesis, it has stimulated a search for peripheral a-syn biomarkers as possible diagnostic, prognostic, and treatment-monitoring markers of prodromal as well as clinically manifest PD (10) . As gastrointestinal symptoms including constipation, dysphagia and delayed gastric emptying are clinical features of PD and possibly prodromal PD, and because colonic biopsy cancer screening is performed on a large subset of the normal middle-aged population, much attention has been focused on the diagnostic and prognostic potential of colonic biopsies . Other peripheral sites are also under consideration, notably skin (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) , stomach (7, 30, 48, 49) , esophagus (50, 51) , pharynx (52) (53) (54) (55) , and salivary glands (50, 51, (56) (57) (58) (59) (60) (61) .
The histological identification of peripheral a-syn, however, is not without its own unique set of challenges that need to be overcome before widespread biomarker utility can be achieved. Although some investigators have demonstrated selective, enhanced, or posttranslationally modified a-syn immunoreactivity in multiple peripheral sites of PD individuals compared with healthy controls, with some reports even of prodromal identification, other studies have shown only weaker statistical changes or no changes between PD and control subjects. These variable results may be attributable to different biospecimen collection techniques, biopsy locations, histological methods, and observer criteria and experience. A wide variety of antibodies, as well as divergent fixation, epitope exposure, and signal development methods have been employed. A major shortcoming has been that almost all published studies to date have originated at single centers, with no independent, blinded replication. In addition, clear morphological criteria for what is considered positive or specific staining has generally been lacking and it is often difficult to understand the microanatomical nature of stained structures from the published photomicrographs. Additionally, in most studies, PD has been defined by the clinical diagnosis, which is subject to considerable inaccuracy, ranging close to 50% in early-stage disease (62) .
To attempt to address some of these questions, the Michael J. Fox Foundation for Parkinson's Research (MJFF) held a workshop entitled, "a-Synuclein in Peripheral Tissues," on June 6, 2013. The goal of this meeting, which convened a selected set of investigators already working in the field, was to compare results and methods for colonic biopsy studies and identify outstanding questions and knowledge gaps around the detection of pathological a-syn in other peripheral tissues (submandibular gland and skin). The MJFF subsequently funded several projects and a second meeting, held in July 2015, to probe unresolved issues.
These meetings were used as organizing exercises leading to subsequent commissioned studies, some of which are now published and some of which will be presented for the first time here. It is felt that the meetings and projects have helped to clarify outstanding questions. This article combines a distillation of this work along with a literature review of much of what has been published to date.
Brief Literature Summaries: Colon Studies
The laboratories led by Pascal Derkinderen and Franck Letournel in Nantes, France, made the earliest substantial contribution to a-syn colon studies and have continued to provide the most illuminating work using whole-mounts of microdissected submucosa. In 2008, they were the first to use a-syn immunohistochemical (IHC) methods (for a-syn phosphorylated at serine 129) to describe PD-associated neuritic pathology in the colon (19) ; they later reported on the partial colocalization of this with tyrosine-hydroxylase-positive neuronal fibers (17) , as well as its layer-related (myenteric plexus > submucosal plexus) (20) and rostrocaudal (ascending > descending > rectum) distribution (13) . These selective distribution patterns agree with earlier and later autopsy and biopsy studies (2, 24, 50, 28) . The group found that while the specificity of pathological a-syn was very high, the prevalence of pathological a-syn in PD subjects, even with 8 or more biopsies, was considerably <100%, and within those who were overall positive, some biopsies were negative and the densities of a-syn-immunoreactive nerve fibers showed considerable variability. Clinical correlations showed no relationship to disease duration but significant positive relationships with Unified Parkinson's Disease rating scale axial motor scores, levo-DOPA unresponsiveness, and chronic constipation (17) .
Subsequent studies by other groups have been performed almost entirely on formalin-fixed, paraffin-embedded (FFPE) tissue samples. These have the advantage of being readily accessible to most hospital-based laboratories but the disadvantage of being a much smaller sample of colonic tissue unless numerous sections are cut and stained (adding cost and effort for technicians and pathologists). Such FFPE tissue often has less sensitivity for IHC (63) (64) (65) (66) , principally due to the high temperature or other aspects of paraffin infiltration that can result in masking of epitopes (67) . Fortunately for PD studies, FFPE material, even with very prolonged fixation durations, has been shown to retain strong and selective immunoreactivity for a-syn pathology, especially in combination with appropriate pretreatments that serve the dual purpose of digesting normal a-syn and exposing epitopes masked by fixation and paraffin embedding (68) . Additionally, the automation of staining possible with FFPE sections reduces methodological variability and allows the rapid adoption and standardization of IHC procedures between laboratories (64, 69) .
The studies by Shannon and Kordower encouraged the field by finding a-syn pathology in sigmoid colon biopsies of both early (16) and prodromal PD (15) . Studies from a group centered in Barcelona suggested, however, that only a minority of PD and idiopathic REM sleep behavioral disorder (iRBD) subjects have specific a-syn pathology (14, 24, 34) . Stokholm et al (11) found a greater percentage of iRBD cases to be positive for phosphorylated a-syn but 26% of controls were also positive. In a study of archived biopsies from 62 PD subjects, Hilton et al (22) largely agreed with the Barcelona group in that a-syn pathology was present in only a small minority of prodromal and symptomatic PD subjects.
One of the reasons for these discrepant results might be that antibodies raised against unmodified a-syn may recognize multiple forms of a-syn and stain (without appropriate predigestion by proteases), few, many, or most of the neural elements that normally express a-syn in both control and PD peripheral tissue. Munoz et al were among the first to report this (23, 37, 70) , and this has since been corroborated by several groups (11, 26, 30, 34, 35) . The typical prolonged formalin fixation and paraffin embedding done for postmortem brains eliminates most normal a-syn immunoreactivity but the lighter fixation used for biopsies may result in considerable residual normal a-syn staining. It seems necessary, therefore, to employ proteinase K or other proteases to eliminate such staining from biopsy tissue while preserving the pathological a-syn aggregates (68) . Other approaches to this problem have used antibodies to phosphorylated a-syn (68) or other purportedly pathologyspecific, posttranslational a-syn modifications, such as nitrosylation or truncation (14, 16, 35) , but a consensus on the most sensitive and specific methodology has not yet been achieved.
Reports of aggregated or phosphorylated a-syn in normal colons have raised questions as to whether these are truly specific for PD. Bottner et al (71) found phosphorylated a-syn in the majority of colectomies from neurologically normal subjects. Visanji et al (72, 73) utilized the PET blot method preceded by digestion with proteinase K (which has been shown to be effective for the analogous detection of pathological aggregated prion protein ) and found that while a high percentage of PD subjects were positive, so were all of the controls (26, 27) .
Careful biochemical studies would be a helpful aid to understanding the existence, cellular distribution, and function of a-syn and its posttranslational modifications in the colon and other peripheral organs. Such studies are scarce but indicate considerable spatial and biochemical complexity (74) , as well as methodological challenges.
Skin Studies
The group headed by Roy Freeman at Harvard was the first to report on the possible utility of skin a-syn alterations in PD using an antibody to unmodified a-syn, with Zambonifixed tissue sectioned on a freezing microtome into thick (50 mm) sections (75) . The antibody potentially recognizes both normal and posttranslationally modified a-syn (including phosphorylated a-syn). The group reported that the density of a-syn-immunoreactive nerve fibers, after normalization to total nerve fiber density, was significantly increased in PD patients compared with controls. This was seen in cutaneous sympathetic adrenergic fibers innervating the piloerector muscles and sympathetic, cholinergic fibers innervating the sweat glands but not in cutaneous sensory fibers. They also found that greater normalized a-syn fiber densities were associated with higher Hoehn and Yahr scores and with measures of sympathetic and parasympathetic nervous system function (75) .
In a recent follow-up study that included participants at an earlier PD disease stage of short duration and without autonomic dysfunction, the group found that these subjects also have significantly greater amounts of cutaneous a-syn than control participants, that is sufficient to serve as a diagnostic biomarker with >90% sensitivity and specificity (76) . Several anatomical sites were sampled, including lateral distal leg, distal thigh, proximal thigh, and midvolar forearm, without significant differences in results.
Others have investigated skin biopsies with similar, thick skin sections but with divergent results. Donadio et al (39, 40, 77) has reported a-syn pathology in the cervical region in all PD subjects and no controls. Doppler et al, assessing distal and proximal leg, back, and finger, found that 16/31 PD subjects were positive (43) , and Haga et al (38) reported only 2/38 PD patients were positive with chest and leg biopsies (38) . All of these investigations used antibodies to phosphorylated a-syn.
A number of other studies have been done using FFPE material, again with mixed results. These include Ikemura et al (45) who found phosphorylated a-syn in upper extremity and abdominal skin of 70% of autopsied PD subjects, Beach et al (50) , and Gelpi et al (24) , who both reported no phosphorylated a-syn in abdominal skin from a combined total of 36 postmortem subjects with PD and other Lewy body disorders, Miki et al (78) , who found phosphorylated a-syn in chest wall and leg of 2/20 biopsied PD subjects, Zange et al (47) , who found phosphorylated a-syn in upper extremity skin in 100% of PD biopsied subjects and no controls, and Navarro-Otano et al (46) , who reported no phosphorylated a-syn in distal leg skin from 6 biopsied PD patients.
It is possible that some of the discrepancies between studies may be due to the loss of cutaneous autonomic nerves over the course of the disease. It has been suggested that physiological tests of dermal autonomic function, such as sweat tests, might be used to guide the selection of a suitable biopsy site (45, 44) , but a literature search did not reveal any publications documenting the effectiveness of this approach.
Salivary Gland Studies
Two groups, led by Braak and Del Tredici in Germany, and Beach and Adler in Arizona, published simultaneously that the submandibular gland was positive for a-syn pathology in a high proportion of autopsied PD subjects (50, 56) . Shortly after this, Cersosimo et al (60) reported that 2 of 3 PD patients and none of 3 controls had a-syn pathology in biopsied minor (labial) salivary glands. Subsequent work in larger numbers of PD subjects indicated that the minor salivary glands were a-syn pathology-positive in only a small minority of subjects (57, 61) . The Arizona group went on to explore the feasibility of both submandibular gland and minor salivary glands by needle biopsy, completing 2 small clinical trials (57) (58) (59) . The first trial was performed in late (>5 years duration), while the second was restricted to early PD (<5 years duration). Only a very small proportion of PD subjects were positive for a-syn pathology in the minor salivary glands; therefore, these were not biopsied in the second trial. Combining the results from both trials (total of 40 PD and 10 controls), the submandibular gland was positive for phosphorylated a-syn neuritic staining in 74%-75% of PD subjects while 22% of controls (included in second study only) were also positive. The positive controls are being followed to determine whether they may represent prodromal PD or prodromal dementia with Lewy bodies (DLB) because DLB subjects have been found by the Arizona group to have a moderately high prevalence of a-syn pathology (51) .
The Barcelona group has recently published the results of submandibular gland needle biopsy in 21 subjects with iRBD and 24 with PD (79) . Controls consisted of 26 subjects, derived from normal volunteers undergoing elective neck surgery and autopsies. Phosphorylated a-syn was detected in the nerve fibers of the glandular parenchyma in 8/9 (89%) with iRBD, 8/12 (67%) with PD and none of the controls.
A possible limitation to submandibular gland needle biopsy has been the failure to obtain glandular tissue in some patients. The Barcelona group obtained glandular tissue in only 47% of patients while the Arizona group acquired glandular tissue in 76%-80% (57, 58) . The usage of ultrasound guidance might have been expected to be of assistance but the Barcelona group, which used it, had a higher rate of biopsy failure than the Arizona group, which did not. The Barcelona group found no higher tissue-acquisition rate with increased punctures (between 2 and 4 were done).
Both groups found the procedure to be safe and well-tolerated. Swelling, bruising, and local pain, as expected, was common, but no serious adverse events were recorded for any of the 3 trials, with a total of more than 100 subjects biopsied. The Barcelona group found that the incidence of minor adverse events was significantly correlated with increasing number of needle punctures.
Colon Project 1: Evaluation of a-Synuclein IHC Methods for the Detection of Lewy-Type Synucleinopathy in Gastrointestinal Biopsies
This published project was directed at resolving the discrepant reports regarding the prevalence of a-syn pathology in colonic biopsies (80) . For this purpose, a panel of expert investigators (from laboratories headed by Munoz, Beach, Kordower, and Derkinderen) participated; they were asked to stain identical sets of paraffin-embedded sections from colonic biopsies with their own optimized method. Nine PD patients (chosen from among 29 subjects that had been recruited from the movement disorder clinic in Nantes University Hospital, France for a previously published whole-mount study of colonic synucleinopathy in submucosal biopsies (17) ) were included in the study. From the same study, a set of 3 subjects (out of 10 in the original study) requiring a total colonoscopy for colorectal cancer screening were included as controls.
Four unstained FFPE sections from each block (each block containing 1 or more biopsy tissue fragments) were sent by the Nantes laboratory to the 3 other participating testing laboratories. Each participating lab as well as the central lab stained the full set of sections with their optimal immunoperoxidase method for enteric synucleinopathy. Three different antibodies and 4 different signal development methods were used; 3 groups used antibodies against phosphorylated a-syn while 1 group used an antibody against unmodified a-syn.
Preliminary observation (without a preconceived bias as to what type of staining should be regarded as positive) indicated that 4 major staining patterns were present ( Fig. 1) , including (1) granular staining in the lamina propria, (2) perivascular and/or vascular wall puncta and/or very short fine fibers, (3) granular-lacy staining in the submucosa, and (4) epithelial nuclear staining. Custom templates were constructed to allow separate semiquantitative grading of the 4 patterns by 5 readers blinded to the diagnoses. Grades were assigned as none, sparse, moderate, and frequent at the site of maximum density, converted to numerical values (0-4) for statistical analysis.
Regarding the ability to discriminate between control and PD subjects, the overall impression was that this was not accomplished by any of the staining methods or morphologically defined staining types. Positive staining in densities similar to those seen in PD cases was seen in most of the slides from control cases with most of the staining methods and templates used, as determined by most of the readers. This study was limited, however, in having only 3 control cases and it is possible that if it was repeated with more controls, the diagnostic accuracy of some of the methods might be higher. Another limitation was the absence of submucosa or blood vessels for many of the slides. In conclusion, this study produced results that were not definitive but suggest that the tested methods and/or staining patterns were not adequate for the prediction of PD from typical colonic biopsies. This failure may also have been due, however, to the relative rarity of neuronal elements in the typically small colonic biopsies.
Colon Project 2: Multicenter Blinded-Panel Assessment of IHC Methods for a-Synuclein Pathology in Sigmoid Colon from PD and Control Subjects
The objective of this second study was to evaluate several IHC methods in large, full-thickness sigmoid colon FFPE sections from autopsied PD and control subjects (81) . There were at least 2 reasons for using colon autopsy specimens in this second study, rather than biopsy specimens. First, the unequivocal presence or absence of PD in each autopsied subject had been established through clinical evaluation and a full neuropathological examination. The diagnostic error rate of a Immunostaining is brown; counterstain is blue. Calibration bar ¼ 50 mm and serves for A-D. The granular lamina propria staining was seen to some extent in all slide sets. The perivascular-vascular pattern and the epithelial cell nuclear pattern were both seen in slides stained by 2 of the labs while the submucosa lacy-granular pattern was seen only in slides stained by 1 lab. See original publication for details (80) .
clinical diagnosis of PD ranges from 15% to 50%, depending on disease duration (62) . Second, autopsy specimens are much larger than biopsy specimens and include abundant submucosa as well as the muscularis layer with their respective neuronal plexuses, giving a greater probability that the specimen will contain adequate densities of neuronal structures.
Alternating section sets of sigmoid colon from 5 PD and 5 control subjects were provided by the Arizona group (82) . The PD subjects were chosen from among those with documented higher density scores in the submandibular gland and esophagus (ie, 2 of the peripheral sites routinely tested for a-syn pathology by the Arizona group), on the assumption that these subjects would also be likely to have higher a-syn pathology densities in other peripheral nervous system (PNS) locations.
Alternating sets of 5 sections were sent to each of 4 participating laboratories, who each stained 1 or more of the section sets with their own optimized method and/or an assigned method (the same 4 labs that had participated in colon Project 1). Eight different IHC methods were used (Table 1 ). Primary antibodies included 1 polyclonal and 3 different monoclonal antibodies against a-synuclein phosphorylated at serine 129 (Methods 1-6), as well as 1 monoclonal antibody against a-synuclein without posttranslational modifications (Method 7). Five different combinations of epitope exposure pretreatments and signal development protocols were used.
Stained sections were graded for semiquantitative densities while blinded to diagnosis by the same 4 raters that performed this function for Project 1. All staining patterns considered to be candidates for a-syn pathology were morphologically consistent with nerve fibers and/or puncta (Fig. 2) . This was confirmed by double staining with a panneuronal marker (81) . Following blinded grading, the score sheets were sent to a statistician, for whom the blind was then lifted.
The primary analysis was for the ability of a subjectlevel positive or negative designation to predict diagnostic status (PD or control). Any a-syn pathology score >0 in any slide from any layer was regarded as defining that subject as positive for a-syn pathology. The diagnostic performance was expressed as sensitivity, specificity, Youden Index (an overall measure of diagnostic accuracy derived from the sensitivity and specificity), and interrater agreement (intraclass correlation coefficient).
The analysis aimed to first calculate diagnostic accuracy and interrater agreement with all colonic layers included, as it was considered likely that the muscularis layer, with its reportedly higher prevalence of a-syn pathology, would be critical for this, and then to repeat the calculations with the muscularis excluded, so as to model the biopsy setting, where the muscularis layer is never obtained.
Interrater agreement and mean diagnostic performance were both poor to moderate when data from all colonic regions (lamina propria, submucosa, and muscularis), templates, and raters were included. Because diagnostic performance with the "perivascular dots" template was uniformly poor with all raters, this pattern of staining was regarded as nonspecific and scores using this template were not utilized in subsequent calculations.
The next sets of analyses were performed after exclusion of results from the muscularis layer, to model the biopsy situation. Diagnostic accuracy was overall fairly similar to that obtained with inclusion of the muscularis layer. Results again showed poor to moderate interrater agreement and diagnostic performance.
In a third set of analyses, only the results from the 2 raters with mean Youden Indices >0.5 were used. The mean diagnostic performance and interrater agreement were then both moderate to very good for 6 methods (Methods 1-6, Table 1 ). Averaging results for both raters, 1 method achieved 100% accuracy; 1 was 80% accurate; 3 other methods all achieved 70% accuracy.
Thus, this autopsy-based Project 2 study, in contrast with the prior biopsy-based Project 1 study by the same group, was successful in identifying several IHC methods with high accuracy for PD. The successful methods all employed monoclonal antibodies against phosphorylated a-syn (Table 1) , combined with protease pretreatment. The differing outcome of the 2 studies was most likely due to several reasons, including: (1) the autopsy specimen was much larger and hence more likely to contain a much larger number of neuronal elements, which may have been absent or very sparse in the biopsy samples; (2) the diagnosis of PD in each autopsied subject had been established through a full neuropathological examination whereas the biopsied subjects had only a clinically based diagnosis; (3) positive or specific staining was defined as that with a morphology consistent with a neuronal origin and/or in an anatomical context consistent with a neuronal origin (eg, within nerve fascicles); and (4) results for individual raters were analyzed and only results from the most accurate raters were used. Although the autopsy study identified several methods with useful accuracy for identifying PD subjects, positivelyand specifically stained nerve fibers were scarce and widely scattered in some subjects. This raised concerns that randomly acquired biopsies may often miss positive sites resulting in a high false-negative rate. Also, the amount of submucosa obtained in typical biopsies is often minimal. If colonic biopsies are to be used for studies of diagnostic accuracy, it was considered that multiple biopsy samples from each PD subject are advisable to increase sensitivity.
Because the PD subjects in this study had long symptom durations, averaging more than 15 years, and were chosen on the basis of previously demonstrated higher PNS (submandibular gland and esophagus), a-syn pathology scores, the prevalences, and densities of peripheral nervous system pathology in this small subset of PD cases are likely to be higher than that expected for the general PD population.
Skin Project 1: Detection of Cutaneous a-Synuclein in Paraffin-Embedded Autopsy Specimens from PD Subjects
In this project, the laboratory headed by Roy Freeman was tasked with the translation of their prior IHC method for unmodified a-syn (75), involving Zamboni-fixed, thick cryosectioned tissue, into the FFPE format. The Arizona group provided scalp and abdominal skin FFPE sections from 11 autopsied PD subjects and 5 nonsynucleinopathy disease control subjects (82) . Skin samples were taken from the scalp and the abdomen at the time of autopsy and were fixed for 2-3 days in 10% formalin and then paraffin embedded. Standard 5-mm-thick sections were immersed in xylene, washed in alcohol, followed by stepwise rehydration, and microwaving to enhance antigen exposure. The primary antibody used to detect a-syn (hereafter termed "total a-syn") was a polyclonal antibody raised against multiple binding sites from amino acids 111 to 131, potentially capable of identifying both normal and posttranslationally modified a-synuclein, including phosphorylated a-syn (75). In preliminary unpublished studies, the group has confirmed costaining of phosphorylated and total asynuclein in multiple samples. The tissue sections were incubated with the primary antiserum at 1:10 000 dilution overnight at 4 C, followed by incubation with biotinylated secondary antibody for 2 hours at room temperature. Following washout, the sections were incubated with Cy3-labeled tyramide for 10 minutes. The tissue sections were then incubated with rabbit anti-PGP9.5 (protein gene product 9.5) overnight at 4 C, followed by incubation with Cy3 conjugated donkey anti-rabbit for 1 hour at room temperature. All tissue sections were examined under a fluorescent microscope (Zeiss-Axioplan2) and autonomic substructures were imaged by confocal microscopy (Zeiss LSM5 Pascal Exciter; Carl Zeiss, Thornwood, NY). The deposition of a-syn within PGP9.5-positive nerve fibers was confirmed by merged confocal images. a-syn immunoreactivity was estimated with a semiquantitative scale and was considered present only if colocalized on a merged confocal image within PGP9.5-positive nerve fibers.
Dermal structures (pilomotor muscles, sweat glands, and arterioles) were seen in more than half of the tissue sections. asyn immunoreactivity in abdominal tissue and scalp tissues, measured using the semiquantitative scale, was greater in PD samples compared with control samples in pilomotor nerves, sudomotor nerves, and vasomotor nerves. There were no differences in results between the scalp and abdominal tissue.
Determination of a-syn immunoreactivity from FFPE autopsy tissue imposes numerous challenges. Most notably, sections are 5-mm-thick and therefore provide only a fraction of the volume of frozen tissue sections. As a consequence, the paraffin-embedded tissue sections have a smaller sampling area. Moreover, in the thinner sections, nerve fibers often appear as "dots" rather than traceable nerve fibers thus a-syn cannot be definitively colocalized within immunostained nerve fibers. Despite these challenges, these studies suggest that cutaneous a-syn can be identified in postmortem tissue from patients with PD.
Skin Project 2: To Determine the Amount of Phosphorylated a-Synuclein in Cutaneous Autonomic Fibers of PD Patients and Controls
Using their Zamboni-fixed, thick cryosections, the Freeman laboratory here compared staining in PD and control subjects using antibodies against unmodified and phosphorylated a-syn. The Beth Israel Deaconess Institutional Review Board approved the study and all subjects signed an informed consent. All subjects underwent a detailed medical history, medical examination, and neurological examination. PD severity was rated by the Unified Parkinson's Disease rating scale and the modified Hoehn and Yahr scale. Examination scores were measured off of PD medications for at least 16 hours. Autonomic symptoms were quantified using the Boston Autonomic Symptom Questionnaire; symptoms ranged from 0 (none) to 10 (maximal).
All study participants underwent autonomic function testing that included tests of cardiovascular parasympathetic function (the heart rate response to deep respiration, the Valsalva maneuver, and active standing) and cardiovascular sympathetic function (the beat-to-beat blood pressure response to a Valsalva maneuver, tilt -table testing to 60 for 10 minutes and active standing for 5 minutes).
Three-millimeter punch skin biopsies were taken from the lateral distal leg, distal thigh, proximal thigh, and midvolar forearm after local anesthesia with 2% lidocaine. Skin biopsies were placed in Zamboni fixative solution for 18 hours and then placed in cryoprotection (20% glycerol and 20% 0.4 M Sorenson buffer). Biopsy tissue blocks were cut by freezing microtome into 50-mm sections. An average of 20 tissue sections was analyzed, with additional sections used in cases where cutaneous dermal substructures (sweat glands, piloerector muscles) were not identified. Fluorescent IHC staining was performed for covisualizing total nerve fibers and sympathetic cholinergic, sympathetic adrenergic, or a-synuclein positive nerve fibers. Complete details of the IHC methods have been reported (75, 83) . The primary antibodies used to visualize total nerve fibers included the panaxonal marker PGP9.5 (Ultraclone, Burlington, NC). The primary antibody used to detect total a-syn was the same as that used in Project 1 earlier. The primary antibodies used detect phosphorylated a-syn and the results obtained are shown in Table 2 . Costaining for PGP9.5 was performed in all tissue sections. All tissue sections were examined under a fluorescent microscope (Zeiss-Axioplan2), and autonomic substructures were imaged by confocal microscopy (Zeiss LSM5 Pascal Exciter). A series of images of optical sections was acquired at 3-lm intervals throughout the depth of the 50-mm section as a z-stack (Carl Zeiss, Lens Plan-Apochromat x20/0.8). Intraepidermal nerve fiber density, sweat gland nerve fibers density, and pilomotor nerve fiber density were analyzed as previously described (75) .
Due to the low levels of phosphorylated a-syn present in tissue, the results of the phosphorylated a-syn method were reported using a semiquantitative 0-3 scale. A score of 0 revealed no phosphorylated a-syn, while a score of 3 was high levels of phosphorylated a-syn in multiple dermal structures.
In this study, there was clear evidence of phosphorylated asyn within autonomic nerve fibers of dermal structures of all individuals with PD and none in control subjects, although nonspecific phosphorylated a-syn was detected in other dermal tissues of both PD and control subjects. However, there was no relationship between phosphorylated a-syn immunoreactivity, disease duration, autonomic function (heart rate variability by paced breathing, Valsalva ratio, orthostatic hypotension, change in blood pressure by Valsalva maneuver), or autonomic symptoms (measured with the Boston Autonomic Symptom Questionnaire).
In contrast, the immunoreactivity of total a-syn was most prominently measured in sympathetic adrenergic nerve fibers contained within the arrector pili muscles but can also be detected in sudomotor (sympathetic cholinergic) nerve fibers. There were modest correlations between the a-syn ratios and autonomic symptoms (correlations coefficients of 0.33-0.43, p < 0.05). Stronger correlations were present between asyn ratios and autonomic test results (correlation coefficients 0.42-0.47, p < 0.01). Figure 3 shows sample images of phosphorylated and total a-syn in skin biopsy tissue sections.
In summary, these data suggest that a-syn immunoreactivity, and specifically the a-syn ratio, is a cutaneous biomarker of PD severity and reflects the stage of the disease and the degree of autonomic dysfunction. The data show that the a-syn ratio, a continuous measure, correlates with both disease severity, and autonomic dysfunction. In contrast, the use of an antibody against phosphorylated a-syn shows higher specificity for a diagnosis of PD and appears more appropriate as a diagnostic biomarker while the total a-syn ratio may be a better biomarker of disease severity and would be a more appropriate biomarker for disease-modifying clinical trials.
Further, the presence of distal autonomic axonal loss in PD requires consideration. Colocalization of a-syn within PGP9.5-positive nerve fibers at distal biopsy sites becomes more challenging in the setting of a distal neuropathy. This challenge can be addressed by normalization relative to the number of nerve fibers.
Other areas needing further study include assessment of the utility of the techniques in prodromal stage PD and in patients with nonmotor features of PD, such as anosmia and REM sleep behavior disorder. Also, the natural history of cutaneous asyn pathological changes is unknown and requires longitudinal study as does the utility of the technique as a prognostic biomarker. Finally, it will be important to carry out reproducibility studies among laboratories using similar or different techniques.
Summary of Submandibular Gland Autopsy and Clinical Investigations by the Arizona Group
The investigations by the Arizona group have been published elsewhere but are reviewed together here. The submandibular gland is located subcutaneously, just inferior to the mandible, making it easily accessible. The submandibular gland is commonly biopsied by needle core for neoplasia and the complication rate is low. What was unknown at the outset of these studies was whether the much smaller needle core samples would have sufficient sensitivity for the detection of a-syn pathology, as compared with the much-larger autopsy tissue blocks. To estimate the feasibility and potential usefulness of needle core biopsy for the in vivo diagnosis of PD, 18-gauge needles were used to obtain 3-4 tissue cores from each of the frozen submandibular glands of 19 PD subjects that were known to be positive for synucleinopathy on large tissue blocks (57) . Cores were fixed in 10% neutralbuffered formalin and embedded in paraffin. Serial sections were immunostained for phosphorylated a-syn. Of the needle cores from the 19 PD subjects, 17 were positive for a-syn pathology. These results suggested that needle core biopsies of the submandibular gland might be a feasible means of identifying a-syn pathology in living PD subjects but that some cases would be missed by a core biopsy.
The group then went on to perform 2 studies investigating the presence of a-syn pathology in submandibular gland needle core biopsies in live patients with PD (58, 59) . The first study deliberately enrolled patients with PD who had a longer disease duration, 5 years, to ensure that the clinical diagnosis of PD was as accurate as possible. As mentioned, the Arizona group had recently published an analysis of PD clinical diagnostic accuracy that found (largely in agreement with previous studies) that the accuracy of a clinical diagnosis, compared with the gold standard autopsy diagnosis, was 88% in longerduration PD subjects but only 53% for subjects with disease durations of <5 years. Therefore for the first biopsy study, they recruited 15 subjects with longer-duration disease to ensure a high diagnostic accuracy rate for the gold standard. Transcutaneous needle core biopsies were performed unilaterally using a commercially available instrument (Max-Core Disposable Core Biopsy instrument, Bard Medical, Covington, GA). The submandibular gland was localized by palpation and local anesthetic (0.5 cc of lidocaine) was injected into the overlying skin. The biopsy needle was inserted transcutaneously to a depth of 22 mm. Between 1 and 5 needle core biopsies were obtained for each patient.
Biopsied tissue was immediately placed in separate single standard plastic cassettes between 2 sponges and fixed in 10% neutral-buffered formalin. After 24 hours fixation at 4 C, the tissue cores were dehydrated in alcohols, infiltrated with paraffin and serial sections cut with a rotary microtome. IHC staining was performed for phosphorylated a-syn. On microscopic examination, 3 of the cases did not have any tissue elements consistent with submandibular gland resulting in a total of 12 cases having identifiable salivary gland tissue. Assessment for a-syn pathology by a neuropathologist (T.G.B.) revealed 9 of the 12 subjects (75%) with microscopically identifiable salivary gland were positive.
This initial needle core biopsy study showed reasonable sensitivity for detecting subjects with long-duration PD. The goal for therapy, however, would be to slow or halt the progression of PD at an early stage, before there is a life-altering loss of function. Unfortunately, clinical trials of early-stage PD are critically hampered by poor clinical diagnostic accuracy with perhaps only 50%-60% of clinically diagnosed PD cases at first visit being confirmed at autopsy (62) . This second biopsy study, therefore, was directed at patients with disease durations of <5 years. Included were 25 PD patients and 10 similarly aged normal subjects. The submandibular gland biopsy procedure was performed using the same methods as in the first study. Between 3 and 6 needle cores were taken unilaterally with a 16-gauge needle and processed as described. Slides were again examined by a single neuropathologist (T.G.B.) who was blinded to clinical diagnosis.
The mean age of the PD cases was 69.8 while that of the controls was 64.7. The mean duration of PD symptoms was 2.6 (SD 1.1) years at the time of biopsy. There were no group differences in the mean number of needle cores taken per subject or in the mean aggregate area of microscopically identified glandular tissue. A total of 8 subjects (23%; 7 PD and 1 Control) had a submandibular gland maximal aggregate area of <2 mm 2 and were arbitrarily defined (prior to unblinding) as insufficient for determining whether a-syn pathology was present. Despite this criterion, 1 PD subject judged to have insufficient tissue was found to be positive and was included in the analysis. Overall, 14 (74%) of 19 PD subjects had positive biopsies. The total number of slides reviewed did not significantly differ between the pathology-positive and negative groups. Of the 9 controls with adequate glandular tissue 2 (22%) had a-syn pathology; clinical follow-up of these subjects is continuing to ascertain whether they may represent incidental Lewy body disease, a likely prodromal stage for PD or DLB. Representative stained biopsy slide photomicrographs are shown in Figure 4E -H.
Minor side effects (mainly swelling and bruising) were common (27/35, 77% of all biopsy subjects) but were transient and no subject sought medical attention for these. The most common side effect was mild-moderate swelling, present in 22 subjects. Bruising was reported by 5 subjects, 3 reported sore throat, and 2 had drainage from the biopsy site. No serious adverse events occurred.
The Arizona group has recently published an updated survey of submandibular gland a-syn pathology in autopsied cases of DLB, PD, and other Lewy body disorders (51) . The results showed a-syn pathology in 42/47 (89%) PD subjects, 20/28 (71%) DLB subjects, 4/33 (12%) Alzheimer's disease with Lewy bodies, and 1/9 (11%) incidental Lewy body disease subjects but none of the 110 control subjects (see Fig.  4A -D for representative images of the staining seen in autopsied glands). 
Invited Submandibular Gland Studies by Other Groups
Two additional groups presented results for submandibular gland at the initial MJFF meeting. These groups were led by Wagner Zago from Prothena Biosciences and Thomas Kremer from F. Hoffman-La Roche.
Both groups stained and blindly graded submandibular gland FFPE section sets from autopsied neuropathologically diagnosed cases provided by the Arizona group. The Prothena group used the 11A5 monoclonal antibody against phosphorylated a-syn (84), as well as an antibody against truncated asyn (85, 86) ; the Roche group used the 5C12 monoclonal antibody against unmodified a-syn (83) . Both groups employed protease pretreatment to digest normal a-syn and for epitope exposure of pathological a-syn.
Both groups found high sensitivity and specificity of their respective methods (Fig. 5) . The Prothena group stained sections from 4 PD cases and 1 DLB case as well as 5 controls, finding 3 PD cases and the DLB case both positive with both of their antibodies while the controls were all negative. The Roche group found 14/15 PD cases were positive while 9 controls were negative.
DISCUSSION The Need for Multicenter, Blinded-Panel Validation Studies
The failure of replication of many published singlecenter studies is a difficulty across all science disciplines. The 2 colon projects summarized here indicate that some of the conflicting single-center reports may be due to variability in histology reader accuracy. With the employment of more rigorous reader training regarding distinctions between specific and nonspecific staining, blinded panels should be able to provide accurate assessments of competing staining methods. Only the colon has been assessed in this rigorous manner but this should be done for other anatomical sites as soon as feasible.
Additionally, because unrelated pathological states, such as inflammation and neoplasia, may destroy or obscure tissue elements within the biopsy, a board-certified pathologist should participate in the evaluation of peripheral biopsies.
Pathological Peripheral a-Synuclein Is Probably Restricted to Neural Tissue
Although it is theoretically possible that peripheral synucleinopathy in PD may be found in multiple tissue types, it seems more likely that, as in other neurological disorders that may be diagnosed by peripheral biopsy, the characteristic pathology will be restricted to neural tissue elements. Neural tissue and subtypes of neural tissue appear to have a selective vulnerability for the development of a-syn pathology. The prion hypothesis provides an additional mechanism whereby a-syn pathology might spread along, and be restricted to, anatomically connected neuronal systems.
The Need for Biopsies with a Sufficiently Large Amount of Critical Tissue Components
The 2 colon projects (as well as the submandibular gland studies summarized here) indicate that biopsies may not always have a sufficient volume of the critical tissue component(s). The critical tissue components are likely to be those with high densities of neural tissue. Most colonic nerve fibers are concentrated in the myenteric and submucosal plexuses; the myenteric is never obtained in biopsies. The submucosal component from any single typical colonic biopsy is most probably too small to give a reasonable chance of finding positive a-syn pathology, even in advanced PD cases. It is possible, however, that, the combined submucosal volume from several biopsies may be sufficient. Submandibular gland biopsies have a relatively high rate of failure to obtain sufficient glandular tissue but this varies considerably among centers; additional training and experience may be able to improve this, both within and between centers. Skin biopsies appear to have no difficulties obtaining sufficient tissue but with FFPE tissue blocks, examination of numerous sections is required due to the relative scarcity of a-syn pathology versus colon and submandibular gland. Future studies should focus on a comprehensive assessment of skin peripheral nerve a-syn pathology in various regions of the body to identify the most suitable site(s) for skin biopsies to find the site(s) with the greatest pathological a-syn densities. The Potential Clinical Utility of Peripheral Tissue Synucleinopathy
The most immediate clinical utility of biopsies for peripheral tissue a-syn pathology is to improve subject selection for clinical trials of therapeutic or neuroprotective agents in early-stage PD. The low clinical diagnostic accuracy rate of a standard neurological examination, even when performed by movement disorders specialists, must be regarded as a critical limitation to the efficiency of such early-disease trials. Improving the diagnostic accuracy with biopsy would result in more PD subjects and fewer non-PD subjects being included in trials.
The published colon work of the Derkinderen group (as well as that of the Freeman group in skin) indicates considerable promise for disease-associated neural a-syn immunoreactivity as a surrogate biomarker for clinical disease severity. A crucial aspect of this work may be the need to normalize the density of a-syn-immunoreactive neural elements against total nerve fiber density because the latter may be reduced in density as disease progresses and nerve fibers die. Serial biopsies over time may indicate whether a-syn pathology reaches an early peak and then declines or continues to increase through the disease course. The usage of standardized, automated IHC methods will also be critical for interlaboratory methods transfer enabling high-throughput, consistent results across multiple observational studies and clinical trials.
Even without a clear correlation with clinical signs and symptoms, biopsy would separate subjects into 2 groups, the positives and the negatives, allowing differential analyses that might save an otherwise negative trial. Blinded clinical follow-up of subjects biopsied to date should be vigorously pursued to ascertain whether clinical course differs according to biopsy findings.
Perhaps the greatest promise for biopsies is as a direct measure of the disease-associated molecular pathology. At present, there is no way to monitor directly the response to anti-synucleinopathy agents, such as a-syn-directed immunotherapy. Repeat biopsies separated in time would provide a means for this provided that the natural history of peripheral a-syn pathology is to increase or remain stable over time. If, as Orimo et al have suggested, peripheral a-syn pathology peaks early in disease and then progressively disappears as nerve fibers die back (87, 88) , then biopsy may not be useful for this.
The Need for a Sufficiently High Level of Accuracy in the Gold Standard Diagnosis
By definition, diagnostic testing of any new method cannot exceed the accuracy of the standard used. Although the clinical diagnosis of longer-duration PD is sufficiently accurate, at 85% or greater, the diagnosis of early-duration PD is inadequate, at only 50% (62). The ultimate gold standard would be autopsy and neuropathological diagnosis (as has been demanded by the US FDA for licensing of PET amyloid ligands), and this should be vigorously pursued for evaluation of peripheral biopsy sites and individual methods. Because early-duration PD patients typically may survive many years, a reasonable strategy would be to follow them clinically with blinded neurological assessments, because persistence of a PD diagnosis beyond 5 years would be associated with a much more accurate diagnosis. Imaging studies of striatal dopaminergic systems may be helpful but these have also not been validated against the autopsy gold standard and do not distinguish between PD and its common differential diagnoses, including progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration (89) . Cardiac imaging with meta-iodobenzylguanidine reportedly gives a high level of diagnostic accuracy (90, 91) ; and tests of autonomic nervous system function may also provide corroborative validation (92, 93) but these would also need to be assessed in sufficiently large sample sizes at autopsy.
Conclusion
This MJFF-initiated series of investigations and meetings has accomplished its major objective. This was to provide clarification as to why existing published reports regarding peripheral synucleinopathy have had discrepant results. The major conclusion was that biopsy is able to accurately distinguish PD from normal subjects but a full assessment of the clinical potential of biopsy will only be achieved through the completion of large, multicenter clinical trials within which both the initial stains selection and the definitive trial histology have been adjudicated by blinded panels of trained histology assessors. Ultimately, even rigorous clinical studies such as these will need to proceed to autopsy confirmation of diagnosis if a fully validated and calibrated viewpoint is to be achieved.
Based on these results, and fueled by the critical need to determine how pathological a-syn alterations in peripheral tissues correlate with each other and with biofluid measures, the MJFF has now launched the Systemic Synuclein Sampling Study (S4). This is a rigorously designed and monitored observational clinical study enrolling individuals with PD as well as control volunteers who will each donate samples of biofluids (cerebrospinal fluid, blood, and saliva), as well as tissues (including skin, colon, and submandibular gland). a-syn concentrations and/or phosphorylation states will be assessed in all of these tissues and fluids in an attempt to identify promising PD biomarkers.
